Holowesko Partners Ltd. cut its stake in Astrazeneca PLC (NYSE:AZN) by 34.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,118,000 shares of the company’s stock after selling 1,103,000 shares during the period. Astrazeneca PLC makes up about 4.9% of Holowesko Partners Ltd.’s portfolio, making the stock its 8th biggest holding. Holowesko Partners Ltd. owned approximately 0.08% of Astrazeneca PLC worth $72,203,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in AZN. Meeder Asset Management Inc. acquired a new position in Astrazeneca PLC in the 2nd quarter valued at $105,000. Salem Investment Counselors Inc. acquired a new position in shares of Astrazeneca PLC during the 1st quarter worth $107,000. Tower Research Capital LLC TRC raised its holdings in shares of Astrazeneca PLC by 3,782.0% during the 1st quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock worth $121,000 after buying an additional 3,782 shares in the last quarter. Parallel Advisors LLC raised its holdings in shares of Astrazeneca PLC by 27.1% during the 1st quarter. Parallel Advisors LLC now owns 4,526 shares of the company’s stock worth $138,000 after buying an additional 964 shares in the last quarter. Finally, Bronfman E.L. Rothschild L.P. raised its holdings in shares of Astrazeneca PLC by 71.2% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock worth $145,000 after buying an additional 1,769 shares in the last quarter. 14.18% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Astrazeneca PLC (AZN) is Holowesko Partners Ltd.’s 8th Largest Position” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/10/astrazeneca-plc-azn-is-holowesko-partners-ltd-s-8th-largest-position.html.

Astrazeneca PLC (NYSE AZN) traded up 1.13% during midday trading on Friday, hitting $32.25. The company’s stock had a trading volume of 5,266,413 shares. The stock has a 50 day moving average of $30.20 and a 200 day moving average of $31.61. Astrazeneca PLC has a 52-week low of $25.55 and a 52-week high of $35.60. The company has a market cap of $81.66 billion, a PE ratio of 21.15 and a beta of 0.74. Astrazeneca PLC also was the recipient of unusually large options trading on Thursday. Stock traders bought 21,026 call options on the stock. This represents an increase of approximately 777% compared to the average volume of 2,397 call options.

Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings data on Thursday, July 27th. The company reported $0.87 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.46. The firm had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The company’s quarterly revenue was down 9.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.83 earnings per share. On average, equities analysts expect that Astrazeneca PLC will post $1.85 EPS for the current year.

The business also recently disclosed a None dividend, which will be paid on Monday, September 11th. Stockholders of record on Friday, August 11th will be issued a $0.44 dividend. The ex-dividend date is Wednesday, August 9th. This represents a dividend yield of 2.98%. Astrazeneca PLC’s dividend payout ratio is currently 44.92%.

AZN has been the subject of a number of research analyst reports. Goldman Sachs Group, Inc. (The) reissued a “sell” rating on shares of Astrazeneca PLC in a report on Thursday, July 13th. Barclays PLC reissued an “overweight” rating on shares of Astrazeneca PLC in a report on Thursday, July 13th. Leerink Swann cut Astrazeneca PLC from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $36.00 to $31.00 in a report on Thursday, July 27th. Zacks Investment Research cut Astrazeneca PLC from a “strong-buy” rating to a “sell” rating in a report on Monday, July 17th. Finally, BidaskClub cut Astrazeneca PLC from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Four research analysts have rated the stock with a sell rating, eleven have issued a hold rating and thirteen have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $33.60.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.